SCHEMBL6044609

SCHEMBL6044609

CNS(=O)(=O)CCN

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Phosphine SCHEMBL28304966 0.97
Hydrochloric Acid SCHEMBL3756983 0.97
SCHEMBL11933655 0.83
Hydrochloric Acid SCHEMBL3754157 0.81 APP (0.44)
SCHEMBL1655493 0.81 RELA (0.42)
SCHEMBL4922033 0.81
SCHEMBL24052340 0.79 RELA (0.44)
SCHEMBL1656935 0.79 RELA (0.44)
SCHEMBL13955204 0.77
SCHEMBL8885972 0.75 LMNA (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109251588-B Inorganic nano material ink, preparation method and application thereof, and QLED device TCL科技集团股份有限公司 2021-06-22 CN claimed
WO-2020234829-A1 METHODS AND COMPOSITIONS FOR INHIBITING GAPDH GEISTLICH PHARMA AG (CH) 2020-11-26 WO claimed
WO-2020234833-A1 METHOD FOR TREATING, PREVENTING, INHIBITING OR REDUCING CYTOKINE RELEASE GEISTLICH PHARMA AG (CH) 2020-11-26 WO claimed
CN-109251588-A Inorganic nano material ink and its preparation method and application, QLED device TCL集团股份有限公司 2019-01-22 CN claimed
US-6828320-B2 Enzyme inhibitors; anticancer agents SMITHKLINE BEECHAM CORPORATION 2004-12-07 US claimed
EP-0912559-B1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LTD (GB) 2002-11-06 EP claimed
US-6391874-B1 ANTICARCINOGENIC AGENTS; SKIN DISORDERS SMITHKLINE BEECHAM CORPORATION 2002-05-21 US claimed
EP-0678503-B1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities NOVARTIS AG (CH) 1999-09-01 EP claimed
EP-0912559-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1999-05-06 EP claimed
WO-1998002434-A1 FUSED HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS GLAXO GROUP LIMITED (GB) 1998-01-22 WO claimed
EP-0156643-B1 ESTER PRODRUGS OF STEROIDS THE UPJOHN COMPANY (US) 1990-08-08 EP claimed
EP-0120557-B1 21-HYDROXYCORTICOSTEROID ESTERS, AND COMPOSITIONS CONTAINING THEM THE UPJOHN COMPANY (US) 1989-06-07 EP claimed
US-20260125384-A1 INDAZOLE INHIBITORS OF CYCLIC GMP-AMP SYNTHASE AND USES THEREOF VENTUS THERAPEUTICS U.S., INC. (US) 2026-05-07 US disclosed
US-12503467-B2 2-oxoquinazoline derivatives as methionine adenosyltransferase 2A inhibitors IDEAYA BIOSCIENCES, INC. (US) 2025-12-23 US disclosed
US-20250248973-A1 CANNABINOID RECEPTOR 1 ANTAGONISTS/INVERSE AGONISTS AND USES THEREOF CORBUS PHARMACEUTICALS, INC. 2025-08-07 US disclosed
US-20250171459-A1 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMA (US) 2025-05-29 US disclosed
US-5627182-A RENIN INHIBITORS FOR USE AS HYPOTENSIVE AGENTS CIBA GEIGY CORPORATION (US) 1997-05-06 US disclosed
US-5559111-A HYPOTENSIVE AGENTS; RENIN INHIBITORS; Aliskiren CIBA-GEIGY CORPORATION (US) 1996-09-24 US disclosed
EP-0678503-A1 Delta-amino-gamma-hydroxy-omega-aryl alkanoic acid amides with enzyme especially renin inhibiting activities CIBA-GEIGY AG (CH) 1995-10-25 EP disclosed
EP-0136266-A2 7-Beta-acylamido-3-cephem-4-carboxylic-acid esters, process for their preparation, pharmaceutical compositions and their application CIBA-GEIGY AG (CH) 1985-04-03 EP disclosed